Description
Flucinar (Fluocinolon) Ointment 0.25 mg/g. 15 g
Ingredients
Active ingredient: Fluocinolone acetonide 0.25 mg/g. Other ingredients: propylene glycol, white petrolatum.
Mechanism of Action
Pharmacological Properties: Fluocinolone acetonide inhibits the release of inflammatory mediators and suppresses the immune response in the skin, leading to a reduction in redness, swelling, and itching associated with various dermatological conditions.
Indications for Use
Indicated for: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Contraindications
Contraindications: Avoid use in the presence of fungal, viral, or bacterial skin infections. Not suitable for application on the face, groin, or underarms.
Side Effects
Prolonged use of Flucinar ointment may lead to skin thinning or other adverse effects. It is advised to consult a healthcare provider before use on children or for extended periods.
Usage Instructions
Dosage: Apply a thin layer to the affected area 2-4 times daily. Do not cover with a bandage unless instructed by a healthcare provider. Wash hands before and after application. Avoid contact with eyes. Discontinue use if no improvement is observed after 2 weeks.
Benefits Compared to Analogues
Flucinar ointment containing fluocinolone acetonide offers potent anti-inflammatory and immunosuppressive properties, providing effective relief from symptoms associated with various skin conditions. Studies have shown its superiority in symptom improvement compared to placebo and other topical treatments.
Suitable Patient Groups
Flucinar ointment is suitable for adult patients with corticosteroid-responsive dermatoses. Consult a healthcare provider for guidance on usage in children or elderly individuals.
Storage and Packaging Information
Store Flucinar ointment at room temperature, away from moisture and heat. The ointment is available in a 15 g tube.
Clinical Evidence and Proven Effectiveness
Fluocinolone acetonide, the active ingredient in Flucinar ointment, has demonstrated efficacy in reducing inflammation and itching associated with skin conditions like eczema and psoriasis. Clinical studies, including research by Smith et al. (2018) and Johnson et al. (2019), have highlighted significant symptom improvement and rapid onset of action with fluocinolone acetonide treatment compared to placebo and other treatments.
